Phase 3 Heart Disease Trial, Recruiting NCT06783166 Sponsor: Mansoura University Condition: Heart Disease
Back to Heart Disease

Phase 3 Heart Disease Trial, Recruiting

NCT06783166
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are in hospital for acute heart failure with fluid buildup (congestion), shown by at least 2 signs such as swollen legs, fluid in the abdomen, shortness of breath when lying down, sudden breathlessness at night, recent weight gain of around 5 pounds, or fluid seen on a chest X-ray or ultrasound — or, if a special heart pressure monitoring line is in place, a high pressure reading plus at least one of those physical signs
  • People enrolled into the trial within 24 hours of being admitted to hospital for acute heart failure
  • People for whom doctors plan to use intravenous (IV) water-removing medication (loop diuretics) during the hospital stay
  • People whose kidneys are functioning at a level of at least 30 ml/min/1.73m² as measured by a standard medical calculation (confirm with trial site)

Who may not be able to join:

  • People who are unable to follow instructions
  • People who have been treated with a specific type of diuretic medication that works on the proximal tubule of the kidney (confirm with trial site for specific medicines)
  • People whose top blood pressure number (systolic) is below 90 mmHg
  • People whose kidney function is measured at less than 20 ml/1.73m² by a standard medical calculation
  • People with Type 1 diabetes
  • People whose breathing difficulties are mainly caused by something other than a heart condition
  • People in cardiogenic shock (when the heart is suddenly unable to pump enough blood)
  • People who have had an acute coronary syndrome (such as a heart attack or unstable chest pain) within the 30 days before enrolment
  • People who have had or are planned to have a heart procedure (such as a stent or bypass surgery) within 30 days before enrolment
  • People showing signs of a dangerous chemical imbalance related to diabetes, such as ketoacidosis or high blood sugar with certain blood test results (confirm with trial site)
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Noha Mansour, PhD, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, University of Mansoura

Phone: +201009648197

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Mansoura University
Registry
ClinicalTrials.gov
Start date
15 August 2024
Est. completion
1 July 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in dyspnea VAS (Visual analogue scale)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov